MedTrace Logo

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

NCT07265466 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2025-12-04

No results posted yet for this study

Summary

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

Conditions

  • Drug Drug Interaction (DDI)

Interventions

DRUG

JP-1366 and clopidogrel

A randomized, open label, multiple-dosing, 6-sequence, 3-period, 3-treatment, crossover design

DRUG

JP-1366 and aspirin

An open-label, multiple-dosing, fixed sequence, 3-period design

DRUG

JP-1366 and atorvastatin

An open-label, multiple-dosing, fixed sequence, 3-period design Period 1: Atorvastatin

DRUG

JP-1366 and apixaban

An open-label, multiple-dosing, fixed sequence, 3-period design

Sponsors & Collaborators

  • Onconic Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
19 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-17
Primary Completion
2026-03-30
Completion
2026-03-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07265466 on ClinicalTrials.gov